Walleye Capital
NKTR icon

Walleye Capital’s Nektar Therapeutics NKTR Stock Holding History

Walleye Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,233
Closed -$883K – 2103
2019
Q3 		$883K Buy
+3,233
New +$1.19M 0.05% 497

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Walleye Capital's NKTR Position: Q1 2026 in Review

Walleye Capital opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 12,878 shares worth $927K. The stake represents ﹤0.01% of the portfolio and ranks #2143 among its holdings. This is a return to the name: Walleye Capital previously reported a position in NKTR as recently as Q3 2025.

Walleye Capital first reported a position in NKTR in Q4 2020 and has held it in 9 quarters since. The position peaked at $2.05M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Walleye Capital held 12,878 shares of Nektar Therapeutics worth $927K as of Q1 2026.
  • Nektar Therapeutics was a new Walleye Capital position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2143 holding.
  • Walleye Capital first reported a position in Nektar Therapeutics in Q4 2020 and has held it in 9 quarters since.
  • Walleye Capital's Nektar Therapeutics position peaked at $2.05M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.